How can scientists leverage AI and machine learning to more effectively research, develop, and deliver new drugs? This week, Reid and Aria talk drug development with renowned computer scientist and executive Dr. Daphne Koller, whose company, insitro, uses machine learning to improve the quality and speed of drug discov

This episode is live from our recent AI Revolutionaries (AIR) conference. In this episode, Daphne Koller, founder and CEO at insitro and AI expert, chats with Vijay Pande of Bio + Health. You can check out the full conversation with video and transcript at https://a16z.com/digital-biology/. 

About this Episode: This week’s guest, Daphne Koller, is the Founder and CEO of Insitro - a company shifting the paradigm of new drug discovery using predictive models. Patrick and Daphne talk about why she founded Insitro, how to create unified datasets, and the importance of being realistic about drug discovery.

Daphne Koller is the CEO and founder of insitro, a machine learning-enabled drug discovery company. Previously, she was a professor of computer science at Stanford University for 18 years, co-founder and co-CEO of Coursera, and the Chief Computing Officer of Calico, an Alphabet company in the healthcare space. She rece

From teaching at Stanford to co-founding Coursera, insitro, and Engageli, Daphne Koller reflects on the importance of education, giving back, and cross-functional research. Daphne Koller is the founder and CEO of insitro, a company using machine learning to rethink drug discovery and development. She is a MacArthur Fel

Former Stanford University professor Daphne Koller's cutting edge work combines machine learning and biology to transform pharmaceutical drug development. Her work at insitro is part of an emerging field - digital biology - that is having an impact on multiple fields, including biomaterial design, agriculture, and huma